Development of an senescence-associated system diagnostic kit for cancer and stroke - SASKit

• Conditions: C25; I63; Malignant neoplasm of pancreas; Cerebral infarction

• Registration Number: DRKS00021184
• Lead Sponsor: niversitätsmedizin Rostock

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-03-27
• Study Completion: 2024-04-01
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

Newly diagnosed Adenocarcinoma of the pancreas in the advanced or metastatic stage, no previous system therapy

or

Ischemic stroke of the supratentorial brain region before 3-10 days (definitive cerebral infarction volume> 10 ml on MRI)

or

Control person who is neither brother nor sister and has an age difference of no more than 12 years.

Exclusion Criteria

- Age <18 years
- previous or current medical tumor therapy
- other cancer within the past 2 years
- previous stroke with persistent deficit
- myocardial infarction within the past 2 years
- therapeutic anticoagulation, within the past 2 years up to the time of study enrollment, for a duration of more than 1 month

The exclusion criteria are described in detail in our study protocol (Henze et al., BMJ open 10:e039560, 2020, PMID 33334830)

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary objective is a combined endpoint defined as the first deterioration of one of the <br>following:<br>probable sarcopenia, deterioration of ECOG PS or mRS (respectively), deterioration of quality of life evaluated by EQ-5D-L. <br>It is described in detail in our study protocol (Henze et al., BMJ Open 10:e039560, 2020, PMID 33334830). <br><br>

Secondary Outcome Measures

Name	Time	Method
Secondary objectives are:<br>new vascular event, <br>new cancer, <br>probable sarcopenia, <br>cognitive decline, <br>frailty (CSHA-CFS), <br>all cause mortality. <br><br>The secondary objectives are described in detail in our study protocol (Henze et al., BMJ Open 10:e039560, 2020, PMID 33334830)